Below is a list of studies we’ve done in the past.

  • Meningitis for infants (Met41)
  • Obesity Genetic Testing
  • Pediatric Obesity
  • Parainfluenza in toddlers using mRNA
  • CMV using mRNA
  • Pediculosis Capitis.
  • Head Lice Infestation Treatment
  • Type 2 Diabetes Mellitu Oral Semaglutide  vs Sitagliptin
  • Lira Prime Efficacy in controlling glycaemia with Victoza 
  • Lesinurad 200mg in Combinationwith a XanthineOxidase Inhibito
  • Study to Evaluate the Efficacy and Safety of ORMD-0801 in Type 2 Diabetes Mellitus Patients with Inadequate Glycemic Control on Oral Therapy
  • Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with or at High Risk for Cardiovascular Disease who are Statin Intolerant
  • Efficacy and safety of two doses of favipiravir in older patients with uncomplicated influenza
  • oseltamivir doses in influenza patients with pandemic (H1N1) 2009FLU
  • A Dapagliflozin study in patients with type 2 diabetes and cardio vascular disease
  • Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients with Type 2 Diabetes
  • Safety and Tolerability of ITCA 650 in Patients with Type 2 Diabetes with High BaselineHbA1c
  • Evaluated Cardiovascular Outcomes with ITCA650 in Patients Treated with Standard of Care for Type 2 Diabetes
  •  Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) versusOseltamivir for the Treatment of Influenza in Adults at Risk for Complications
  • CMV traditional vaccine
  • HPV vaccine in males
  • Type 2 Diabetes studies
  • Testosterone in Men\
  • FluMist Compared with (TIV) in Children
  •  (MMRV) versus ProQuad
  • Respiratory Syncytial Virus in children
  • Type 2 Diabetes Study to Assess Cardiovascular Outcomes  with Ertugliflozin 
  • MYL-1501D Produced by Two Manufacturing Processes in Type 1 Diabetes Mellitus Patients
  • Stain Residual Risk Reduction with EpaNova in High Cardiovascular Risk Patients with Hypertriglyceridemia 
  •  Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenza
  • A “factorial” design, 12-month study to evaluate the efficacy and safety of AVE5530 25 mg/day and 50 mg/day co-administered with all registered atorvastatin
  • A safety and tolerability of multiple oral doses of ASP1941in subjects with type 2 diabetes mellitus
  • Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors
  • Combination of Ertugliflozin with Sitagliptin in the Treatment of Subjects with T2DM with Inadequate Glycemic Control on Diet and Exercise
  • Safety, and Tolerability of VK 2809 Administered for 12 Weeks Followed by a 6-Week Off-Drug Phase in Patients with Primary Hypercholesterolemia and a Non-Alcoholic Fatty Liver Disease
  • Evaluate the Efficacy and Safety of Tenapanorfor Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
  •  Study of APT001Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers
Copyright © 2020 Crossroads Clinical Research